The Emerging Technologies and Therapeutics Reports provide timely summaries of evidence supporting new drugs, devices, and other healthcare technologies that are recently in use or may be available in the near term in the United States.

These reports also identify gaps that need to be addressed for the technologies or therapeutics to move forward. The issue brief succinctly spotlights information from the Emerging Technologies and Therapeutics Reports.

Genomic Sequencing to Guide Cancer Management

View Award Page

Review Report (Published July 2021)

This review of commercially available next-generation sequencing tests for cancer management includes 321 published clinical research studies.

Read Report

Issue Brief (Published December 2021)

This issue brief discusses the current use of genomic sequencing, regulation, and evidence, as well as the challenges and opportunities ahead.

View Issue Brief

Narrative Review and Evidence Mapping of Artificial Intelligence in Clinical Care

View Award Page

Narrative Review Report (Published February 2021) and Evidence Map

Recognizing the importance of this emerging technology and the potential of artificial intelligence (AI) to improve health for all, this report focuses on applications of AI in health that are currently in use or may be in use in the near future.

Read Report View Evidence Map Read Related Blog

Issue Brief (Published July 2021)

This issue brief describes AI applications currently in use and on the horizon, evidence for AI in clinical medicine, and challenges and opportunities ahead.

View Issue Brief

Narrative Review and Evidence Mapping of Proteomics for Cancer and Cardiovascular Disease

View Award Page

Narrative Review Report (Published January 2021)

Proteomic testing has been proposed for a wide variety of applications and conditions. This report offers a narrative review and evidence maps for proteomics for cancer and cardiovascular disease.

Read Report

Issue Brief (Published August 2021)

This issue brief describes proteomic applications currently in use and on the horizon, evidence for proteomics in clinical medicine, and challenges ahead.

View Issue Brief

Landscape Review and Evidence Map of Gene Therapy

View Award Page

The purpose of this report is to better understand the evidence supporting currently approved gene therapies and those that may be available in the near term in the United States. Because the literature base across all of the interventions is so large, we split the content into 2 parts.

Report Part I (Published March 2019)

Part I of the report focuses on adenovirus, adeno-associated virus vector-based (AAV) gene therapy, and clustered regularly interspaced short palindromic repeats (CRISPR). It addresses the description of the interventions, the context in which gene therapy is used, ongoing premarket and postmarket gene therapy studies, and current evidence for the use of gene therapy.

Report Part II (Published June 2019)

Part II of the report focuses on chimeric antigen receptor T cell (CAR-T); autologous cell; zinc finger nuclease (ZFN); antisense; ribonucleic acid interference (RNAi); and oncolytic viral therapy replication-competent, attenuated derivative of herpes simplex virus type 1 therapies.

Read Report (Part I) Read Report (Part II)

An Evidence Map of Randomised Controlled Trials Evaluating Genetic Therapies

BMJ EVIDENCE-BASED MEDICINE (Published November 2020)
Apaydin EA, Richardson AS, Baxi S, Vockley J, Akinniranye O, Ross R, Larkin J, Motala A, Azhar G, Hempel S. An evidence map of randomised controlled trials evaluating genetic therapies. BMJ Evid Based Med. 2020 Nov 10:bmjebm-2020-111448. doi: 10.1136/bmjebm-2020-111448. Epub ahead of print. PMID: 33172937.

View Journal Publication

Issue Brief (Published July 2019)

This issue brief discusses approved therapies and those on the horizon, as well as the challenges and opportunities ahead.

View Issue Brief

B-cell Lymphoma and Non-Hodgkin’s Lymphoma Treatment: How Do Participants of Chimeric Antigen Receptor T-cell Therapy Research Studies Compare With Patients in the US Population? (Published June 2020)

Human gene therapy has evolved rapidly, and chimeric antigen receptor T-cell (CAR-T) therapy appears to be a promising treatment for B-cell lymphoma and non-Hodgkin’s lymphoma. This report compares participants of CAR-T therapy research studies to individuals living with the diseases in the US population.

Read Report

Posted: June 11, 2019; Updated: December 17, 2021